[I:1][C:2]1[CH:7]=[CH:6][C:5]2[C:8]3[CH2:13][CH2:12][NH:11][C:10]([CH2:15]N4C(=O)C5C(=CC=CC=5)C4=O)([CH3:14])[C:9]=3[O:27][C:4]=2[CH:3]=1.[CH2:28](O)C.[OH2:31].NN.[N:34]1[CH:39]=[CH:38][CH:37]=CC=1>C(Cl)Cl.O>[I:1][C:2]1[CH:7]=[CH:6][C:5]2[C:8]3[CH2:13][CH2:12][NH:11][C:10]([CH2:15][C:38]([CH3:28])([CH3:37])[C:39]([NH2:34])=[O:31])([CH3:14])[C:9]=3[O:27][C:4]=2[CH:3]=1
A suspension of 2-(7-iodo-1-methyl-1,2,3,4-tetrahydro-benzofuro[2,3-c]pyridin-1-ylmethyl)-isoindole-1,3-dione (0.472 g, 1.00 mmol) in ethanol (10.00 mL, 171.3 mmol) was refluxed with hydrazine monohydrate (200 mg, 4 mmol). After 4 h, cooled, filtered, rinsed with MeOH, the filtrate concentrated and dried under vacuum. The resulting deprotected amine was dissolved in pyridine (5.00 mL, 61.8 mmol) and propanoic acid-2-methyl-anhydride (0.332 mL, 2.00 mmol) was added. After 1 h at room temperature, water was added (30 mL) and the mixture was stirred overnight. DCM was added and the organic layer was washed with NaHCO3 and evaporated. The crude product was purified using silica gel chromatography using DCM/MeOH/NH4OH to afford (7-iodo-1-methyl-1,2,3,4-tetrahydro-benzofuro[2,3-c]pyridin-1-ylmethyl)-isobutyramide. MS m/z 413 [M+H]+, which was taken directly into the next step.
Loading…
